During Q4 2018 the big money sentiment decreased to 1.1. That’s change of 0.47, from 2018Q3’s 1.57. 25 investors sold all, 45 reduced holdings as Aerie Pharmaceuticals, Inc. ratio dropped. 55 grew stakes while 22 funds acquired stakes. Funds hold 45.76 million shares thus 4.14% more from 2018Q3’s 43.94 million shares.
Aperio Gp Limited Liability holds 6,846 shs or 0% of its capital. Columbus Circle Invsts holds 598,830 shs. Bailard has invested 0.02% of its capital in Aerie Pharmaceuticals, Inc. (NASDAQ:AERI). Citadel Advisors Limited Liability Com has invested 0.03% in Aerie Pharmaceuticals, Inc. (NASDAQ:AERI). Proshare Advisors Llc has invested 0% in Aerie Pharmaceuticals, Inc. (NASDAQ:AERI). Stifel Fin Corporation, a Missouri-based fund reported 86,836 shs. Rhumbline Advisers has 0% invested in Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) for 47,468 shs. Principal Financial Gru holds 0% of its capital in Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) for 15,466 shs. Glenmede Na invested in 0% or 3,575 shs. Charles Schwab Invest Inc has 205,886 shs for 0.01% of their capital. Moreover, Cwm Ltd Limited Liability Company has 0% invested in Aerie Pharmaceuticals, Inc. (NASDAQ:AERI). Suffolk Capital Mngmt Limited Liability Com stated it has 1.59% in Aerie Pharmaceuticals, Inc. (NASDAQ:AERI). Neuberger Berman Grp Lc has 0.02% invested in Aerie Pharmaceuticals, Inc. (NASDAQ:AERI). Endurance Wealth Mgmt holds 0% or 500 shs in its capital. Sg Americas Llc owns 11,378 shs for 0% of their capital.

Aerie Pharmaceuticals, Inc. had 7 selling transactions and 1 buying transaction since September 13, 2018. This’s net activity of $8.00 million. On Friday, February 1 Kopczynski Casey C. sold $507,844 worth of Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) or 11,000 shs. $83,493 worth of stock was bought by Cagle Gerald D. on Friday, November 16.

Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) Ratings Coverage

In total 7 analysts cover Aerie Pharmaceuticals (NASDAQ:AERI). “Buy” rating has 7, “Sell” are 0, while 0 are “Hold”. (NASDAQ:AERI) has 100% bullish analysts. 11 are the (NASDAQ:AERI)’s ratings reports on Mar 11, 2019 according to StockzIntelligence Inc. On Friday, March 1 the stock has “Buy” rating by Mizuho. On Tuesday, February 26 the firm has “Buy” rating by JMP Securities given. On Monday, March 4 the company was maintained by Canaccord Genuity. On Friday, February 22 Mizuho maintained Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) rating. Mizuho has “Buy” rating and $77 target. On Thursday, February 21 the stock of Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) has “Buy” rating given by Oppenheimer. On Tuesday, February 26 the rating was maintained by Cantor Fitzgerald with “Buy”. On Tuesday, February 26 Cowen & Co maintained Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) with “Buy” rating. On Tuesday, February 26 the firm has “Buy” rating given by H.C. Wainwright. On Friday, March 8 the rating was maintained by Mizuho with “Buy”. Listed here are Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) PTs and latest ratings.

08/03/2019 Broker: Mizuho Rating: Buy New Target: $77 Maintain
04/03/2019 Broker: Canaccord Genuity Rating: Buy New Target: $73 Maintain
01/03/2019 Broker: Mizuho Rating: Buy New Target: $77 Maintain
27/02/2019 Broker: BidaskScore Rating: Sell Upgrade
26/02/2019 Broker: Cowen & Co Rating: Buy New Target: $105 Maintain
26/02/2019 Broker: H.C. Wainwright Rating: Buy New Target: $73 Maintain
26/02/2019 Broker: Cantor Fitzgerald Rating: Buy New Target: $85 Maintain
26/02/2019 Broker: JMP Securities Rating: Buy New Target: $75 Maintain
22/02/2019 Broker: Mizuho Rating: Buy New Target: $77 Maintain
21/02/2019 Broker: Oppenheimer Rating: Buy New Target: $64 Maintain

Ticker’s shares touched $46.46 during the last trading session after 0.58% change.Currently Aerie Pharmaceuticals, Inc. is downtrending after 7.21% change in last March 11, 2018. AERI has 419,340 shares volume. AERI underperformed by 11.58% the S&P500.

Aerie Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of first-in-class therapies for the treatment of glaucoma and other eye diseases.The firm is valued at $2.13 billion. The Company’s lead product candidate includes Rhopressa, a once-daily eye drop for the reduction of intraocular pressure in patients with glaucoma or ocular hypertension.Currently it has negative earnings. The firm is also developing Roclatan, a once-daily eye drop to reduce IOP that is in Phase III registration trials to treat patients with open-angle glaucoma and ocular hypertension.

For more Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) news announced recently go to: Seekingalpha.com, Nasdaq.com, Nasdaq.com, or Businesswire.com. The titles are as follows: “Aerie Pharmaceuticals Inc. (AERI) CEO Vicente Anido on Q4 2018 Results – Earnings Call Transcript – Seeking Alpha” announced on February 26, 2019, “Aerie (AERI) Q4 Earnings Miss, Rhopressa Gains Traction – Nasdaq” on February 26, 2019, “Aerie (AERI) Q3 Earnings Miss, Rhopressa Gains Traction – Nasdaq” with a publish date: November 08, 2018, “The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trials, Earnings, IPOs – Yahoo Finance” and the last “Aerie Pharmaceuticals to Announce Fourth Quarter and Full Year 2018 Financial Results and Host Conference Call on Monday, February 25, 2019 – Business Wire” with publication date: February 19, 2019.